Key result
Intermittent levosimendan reduces PVR ~48% in an advanced HF case, enabling heart transplant listing.
Why the study?
Levosimendan's selective venodilator property may explain its clinical benefit during group 2 pulmonary hypertension with right ventricular dysfunction, but the mechanisms remain unclear.
Does levosimendan improve clinical outcomes in patients with group 2 pulmonary hypertension and right ventricular dysfunction?
Case Report (n=1)
Does levosimendan improve clinical outcomes in patients with group 2 pulmonary hypertension and right ventricular dysfunction?
Answers are grounded in this paper and cite their sources.
Levosimendan may provide clinical benefits in group 2 pulmonary hypertension through selective venodilation and improvements in right ventricular contractility.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bernardi et al. (2025) conducted a case report in Advanced heart failure with reduced ejection fraction and pulmonary hypertension (n=1). Levosimendan was evaluated on Pulmonary vascular resistance. Intermittent levosimendan infusion in a 61-year-old woman with advanced heart failure reduced baseline pulmonary vascular resistance from 8.2 to 4.3 Woods units, enabling heart transplant listing.
Synapse has enriched 10 related papers. Consider them for comparative context: